A recent consensus by the European Organization for Research and Treatment of Cancer (EORTC) suggested to define blood involvement (B2 according to the TNMB classification) [1] on the basis of phenotypical criteria in the presence of more than 1,000/mm3 CD4+CD26- or CD4+CD7- cells [7]. Here, CD4 is linked to cancer.